Effect of essential oil TTO and LEO coating of MWCNT filters on bacterial removal rates. by Xiuli Dong (658906)

Subjects:

Inactivation rate of the LEO-MWCNTs filters to <i>E</i>. <i>coli</i> cells captured on the filters with different incubation time after the filtering step. by Xiuli Dong (658906)

Subjects:

Log of <i>E</i>. <i>coli</i> cell numbers in filtrates after filtering through MWCNT filters with different MWCNT loadings. by Xiuli Dong (658906)

Subjects:

Inactivation rates of <i>E</i>. <i>coli</i> bacteria retained on the surfaces of LEO-MWCNTs, TTO-MWCNTs, or Mix-MWCNTs filters with 10, 20 or 50 μL EO coatings. by Xiuli Dong (658906)

Subjects:

Half-maximal inhibitory concentration (IC₅₀), half-maximal cytotoxic concentration (CC₅₀), and selectivity index (SI) of CTLL formulation and its ingredients. by Prapaporn Chaniad (9761710)

Half-maximal inhibitory concentration (IC₅₀), half-maximal cytotoxic concentration (CC₅₀), and selectivity index (SI) of PSCD formulation and its ingredients. by Prapaporn Chaniad (9761710)

In house finch Harderian glands, we identified ˜90% fewer differentially expressed genes when comparing non-infected controls to MG-infected birds from populations that are more to... by Amberleigh E. Henschen (3257235)

Definitions of the features selected [50]. by Yu Zhang (12946)

Effect of Safr and Cands on the levels of complex I (U/mg protein), complex II (U/mg protein), complex IV (U/mg protein), caspase-3 (Casp-3, μg/mg protein), Fas ligand (FasL, μg/mg... by Nagwa Ibrahim Shehata (17319689)

Subjects:

Fig 2 - by Nida Mansoora (11648641)

Subjects:

Fig 3 - by Nida Mansoora (11648641)

Subjects:

Fig 4 - by Nida Mansoora (11648641)

Subjects:

Fig 1 - by Nida Mansoora (11648641)

Subjects:

Effect of different treatments on ionic contents like sodium, calcium, potassium, phosphorous and soluble proteins constituents of two wheat genotypes (Markaz 19 and Ujala 16) afte... by Nida Mansoora (11648641)

Subjects:

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Subjects:

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Subjects:

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects: